Myeloma overview – NICE Pathway (Presentation and Diagnosis)
This NICE pathway provides an interactive flowchart of myeloma diagnosis and management using information from both NICE and other sources.
This NICE pathway provides an interactive flowchart of myeloma diagnosis and management using information from both NICE and other sources.
This NICE pathway provides an interactive flowchart of myeloma diagnosis and management using information from both NICE and other sources.
New recommendations from the International Myeloma Working Group (IMWG) on the use of imaging methods in monoclonal plasma cell disorders were recently published in The Lancet Oncology. (1) Overall, the guidelines recommend that more sensitive imaging techniques, such as whole-body CT and MRI, be introduced generally into clinical practices for the diagnosis and management of…
DetailsThe 2nd Oxford Myeloma Workshop was a two-day event (1-2 August 2019) run by Oxford University Hospitals which focused on the current translational research priorities in myeloma. Patient Advocacy and Policy Research Officer, Dr Amy Capper was there to learn about the latest developments. Here are some of her highlights from the programme: Opening the…
DetailsSome drugs used for the treatment of myeloma can increase the risk of venous thromboembolic events. This NICE guidelines outlines how healthcare professionals can manage patients who may be at higher risk of developing VTE in hospital.
This interactive flowchart developed by NICE gives an overview of blood and bone cancer diagnosis, management and treatment as well as NHS service organisation recommendations.
The haematological malignancies patient report outcomes (HM-PRO) measure has been developed to support patients and their clinicians in discussing, addressing and better recording quality of life issues that matter patients.
Access the questionnaire here.
Lenalidomide (Revlimid®) maintenance for myeloma patients who have undergone high dose therapy and stem cell transplantation (HDT-SCT) will be considered for use on the NHS by The National Institute for Health and Care Excellence (NICE) later this year. This announcement comes after updated advice from the manufacturer Celgene and follows publication of data from the Myeloma XI clinical…
DetailsResults from two phase III clinical trials (MAIA and CASSOPIEA) evaluating daratumumab (Darzalex®) combinations for the treatment of newly diagnosed myeloma patients have been recently published. The data provide evidence to support the use of daratumumab for the treatment of newly diagnosed myeloma patients whether they are eligible for high dose therapy and stem cell…
DetailsMyeloma patients at first relapse in Scotland will now be able to access the new treatment of daratumumab (Darzalex®), bortezomib (Velcade®) and dexamethasone on the NHS after it was approved for use by the Scottish Medicines Consortium (SMC). This decision brings Scotland into line with the rest of the UK following the decision by NICE…
Details